Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (51,178) | (25,550) |
| Cash flows from investing activities | ||
| Maturities and redemptions of investments | 67,031 | 37,500 |
| Purchases of property and equipment | (24) | — |
| Net cash provided by investing activities | 67,007 | 37,500 |
| Cash flows from financing activities | ||
| Payments of deferred offering costs | — | (52) |
| Proceeds from exercises of stock options and employee stock purchase plan issuances | 651 | 5 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s capex?
- MapLight Therapeutics, Inc. (MPLT) reported capex of $24K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about MapLight Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude